CLINICAL TRIALS PROFILE FOR AMIDATE

All Clinical Trials for AMIDATE

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT02453373 ↗	Helping Stroke Patients With ThermoSuit Cooling	Recruiting	Geisinger Clinic	N/A	2017-01-25	The aim of this study is to assess the feasibility of using the Life Recovery Systems ThermoSuit Device to induce therapeutic hypothermia (32-34°C) in victims of ischemic stroke. This feasibility clinical study will enroll a total of 30 patients with acute ischemic stroke at four clinical centers. Subjects will receive hypothermia plus conventional therapy (such as IV-tPA and/or neurothrombectomy therapies if indicated). Endpoints will include feasibility of cooling, adverse events, and neurological recovery in comparison with matched historical controls.
NCT02453373 ↗	Helping Stroke Patients With ThermoSuit Cooling	Recruiting	Tulane University School of Medicine	N/A	2017-01-25	The aim of this study is to assess the feasibility of using the Life Recovery Systems ThermoSuit Device to induce therapeutic hypothermia (32-34°C) in victims of ischemic stroke. This feasibility clinical study will enroll a total of 30 patients with acute ischemic stroke at four clinical centers. Subjects will receive hypothermia plus conventional therapy (such as IV-tPA and/or neurothrombectomy therapies if indicated). Endpoints will include feasibility of cooling, adverse events, and neurological recovery in comparison with matched historical controls.
NCT02453373 ↗	Helping Stroke Patients With ThermoSuit Cooling	Recruiting	Life Recovery Systems	N/A	2017-01-25	The aim of this study is to assess the feasibility of using the Life Recovery Systems ThermoSuit Device to induce therapeutic hypothermia (32-34°C) in victims of ischemic stroke. This feasibility clinical study will enroll a total of 30 patients with acute ischemic stroke at four clinical centers. Subjects will receive hypothermia plus conventional therapy (such as IV-tPA and/or neurothrombectomy therapies if indicated). Endpoints will include feasibility of cooling, adverse events, and neurological recovery in comparison with matched historical controls.
NCT02924090 ↗	Hyperventilation Combined With Etomidate or Ketamine Anesthesia in ECT Treatment of Major Depression	Unknown status	University of Manitoba	Phase 4	2016-09-01	This is a randomized controlled study assessing the effect of pre-emptive hyperventilation on ECT seizure duration, cerebral desaturation and remission of depressive symptoms in patients with Major Depressive Disorder. Comparison of etomidate and ketamine on remission of depressive symptoms with and without pre-emptive hyperventilation will also be studied.
NCT01823328 ↗	Ketamine Versus Etomidate for Rapid Sequence Intubation	Completed	Hennepin Healthcare Research Institute	Phase 4	2013-09-01	The purpose of this study is to compare the effectiveness and safety of ketamine and etomidate during rapid sequence intubation (RSI).
NCT01823328 ↗	Ketamine Versus Etomidate for Rapid Sequence Intubation	Completed	Minneapolis Medical Research Foundation	Phase 4	2013-09-01	The purpose of this study is to compare the effectiveness and safety of ketamine and etomidate during rapid sequence intubation (RSI).

Clinical Trial Conditions for AMIDATE

Condition Name

Condition Name for AMIDATE
Intervention	Trials
Complication	1
Depression	1
Intubation	1
Intubation Complication	1

Condition MeSH

Condition MeSH for AMIDATE
Intervention	Trials
Depressive Disorder, Major	1
Depressive Disorder	1
Depression	1
Stroke	1

Clinical Trial Locations for AMIDATE

Trials by Country

+

−

Trials by Country for AMIDATE
Location	Trials
United States	6
Canada	1

Trials by US State

+

−

Trials by US State for AMIDATE
Location	Trials
California	1
North Carolina	1
South Carolina	1
Pennsylvania	1
Louisiana	1

Clinical Trial Progress for AMIDATE

Clinical Trial Phase

Clinical Trial Phase for AMIDATE
Clinical Trial Phase	Trials
Phase 4	4
N/A	1

Clinical Trial Status

Clinical Trial Status for AMIDATE
Clinical Trial Phase	Trials
Completed	2
Recruiting	2
Unknown status	1

Clinical Trial Sponsors for AMIDATE

Sponsor Name

Sponsor Name for AMIDATE
Sponsor	Trials
Tulane University School of Medicine	1
Life Recovery Systems	1
University of Manitoba	1

Sponsor Type

Sponsor Type for AMIDATE
Sponsor	Trials
Other	9

AMIDATE (Etomidate): Clinical Trials, Market Analysis, and Projections

Introduction to Etomidate

Etomidate, commonly known by its brand name AMIDATE, is a short-acting intravenous anesthetic agent used for the induction of general anesthesia and for sedation in critical care settings. Here, we will delve into the current clinical trials, market analysis, and future projections for this drug.

Clinical Trials and Usage

Current Clinical Context

Etomidate is widely used in medical settings, particularly for rapid-sequence intubation (RSI) and in patients with compromised cardiovascular function. Its minimal impact on cardiovascular stability makes it a preferred choice in critical care and emergency settings[3].

Specific Clinical Trials

While there are no specific clinical trials focused solely on etomidate itself, its use is often evaluated within broader clinical contexts. For instance, during the COVID-19 pandemic, etomidate saw increased demand due to its role in managing critically ill patients, especially those requiring rapid-sequence intubation[3].

Market Analysis

Global Market Size

As of 2024, the global etomidate market size was estimated to be around USD 85.25 billion, with projections indicating it will cross USD 124.99 billion by 2037, growing at a compound annual growth rate (CAGR) of more than 3.2% during the forecast period[2][3].

Regional Market Share

• North America: This region currently dominates the etomidate market, holding more than 40% of the global revenue. The market size in North America was estimated at USD 34,245.80 million in 2024 and is expected to grow at a CAGR of 11.7% from 2024 to 2031[3].
• Europe: Europe holds around 30% of the global revenue, with a market size of USD 25,684.35 million in 2024. It is projected to grow at a CAGR of 12.0% from 2024 to 2031[3].
• Asia Pacific: This region is expected to account for the largest revenue share by 2037, driven by favorable government policies and rapidly growing healthcare infrastructure[2][3].

End-User Segmentation

The market is segmented by end-users into hospitals, clinics, ambulatory surgical centers, and others. Hospitals are the primary centers where surgeries are performed, and they hold the largest market share due to the high volume of surgical procedures requiring anesthesia induction and sedation[2][3].

Product Type Segmentation

The fat emulsion segment is anticipated to acquire the largest share during the forecast period due to its lesser side effects and role in energy metabolism and storage during operations[2].

Growth Drivers

Increasing Demand for Effective Anesthetic Drugs

The growing demand for effective anesthetic drugs, especially in emergency and critical care settings, is a significant driver for the etomidate market. The drug's rapid onset and minimal impact on cardiovascular stability make it a preferred choice in these scenarios[3].

Growing Research and Development

Research and development activities, particularly in the context of cardiovascular diseases and trauma care, are also driving the market. Etomidate's use in maintaining hemodynamic stability in critically ill or traumatized patients is a key factor[2][3].

COVID-19 Impact

The COVID-19 pandemic highlighted the importance of etomidate in managing critically ill patients, leading to increased demand and prioritization in production and distribution[3].

Challenges

Postponement of Elective Surgeries

During the COVID-19 pandemic, many elective surgeries were postponed or canceled to free up hospital resources for COVID-19 patients, which temporarily reduced the demand for anesthetics like etomidate in surgical settings[3].

Side Effects and Alternatives

While etomidate is generally well-tolerated, it can have side effects such as adrenal suppression. The availability of alternative anesthetic agents and ongoing research into new anesthetics could pose challenges to the market growth[3].

Key Players

The etomidate market is dominated by several key players, including:

• Pfizer
• Athenex
• AuroMedics
• Zydus
• American Regent
• Hikma
• Mylan
• Par Sterile Products
• Sagent
• Jiangsu Hengrui Medicine
• Jiangsu Nhwa Group[5]

Future Projections

Market Growth

The etomidate market is expected to continue growing, driven by the increasing demand for effective anesthetic drugs, growing healthcare infrastructure, and favorable government policies. The Asia Pacific region is anticipated to account for the largest revenue share by 2037[2][3].

Technological Advancements

Advancements in drug formulation, such as the use of fat emulsions, are expected to boost the market. These formulations offer lesser side effects and play a crucial role in energy metabolism and storage during operations[2].

Regulatory Support

Regulatory support, such as the inclusion of etomidate in essential drug lists during the COVID-19 pandemic, ensures its prioritization in production and distribution. This support is likely to continue, driving market growth[3].

Key Takeaways

• Market Size and Growth: The global etomidate market is projected to grow significantly, crossing USD 124.99 billion by 2037.
• Regional Dominance: North America currently dominates the market, but the Asia Pacific region is expected to grow rapidly.
• End-User Segmentation: Hospitals hold the largest market share due to the high volume of surgical procedures.
• Growth Drivers: Increasing demand for effective anesthetic drugs, growing research and development, and COVID-19 impact are key drivers.
• Challenges: Postponement of elective surgeries and potential side effects are challenges to market growth.

FAQs

What is the current global market size of etomidate?

The global etomidate market size was estimated at USD 85.25 billion in 2024[2].

Which region dominates the etomidate market?

North America currently dominates the etomidate market, holding more than 40% of the global revenue[3].

What are the primary drivers of the etomidate market growth?

The primary drivers include increasing demand for effective anesthetic drugs, growing research and development activities, and the impact of the COVID-19 pandemic[2][3].

Who are the key players in the etomidate market?

Key players include Pfizer, Athenex, AuroMedics, Zydus, American Regent, Hikma, Mylan, Par Sterile Products, Sagent, Jiangsu Hengrui Medicine, and Jiangsu Nhwa Group[5].

What are the expected future projections for the etomidate market?

The market is expected to grow significantly, driven by increasing demand, technological advancements, and regulatory support, with the Asia Pacific region anticipated to account for the largest revenue share by 2037[2][3].

What are the common side effects associated with etomidate?

Etomidate can cause side effects such as adrenal suppression and mild infusion-related events, although it is generally well-tolerated[3].

Sources

1. Innovative Genomics Institute: CRISPR Clinical Trials: A 2024 Update[1].
2. Research Nester: Etomidate Market Size, Forecast Report 2037[2].
3. Cognitive Market Research: Etomidate Market Report[3].
4. Rett Research & Clinical Pipeline: Explore the latest advancements in Rett syndrome research, clinical trials, and therapies[4].
5. Valuates Reports: Global Etomidate Injection Market Research Report 2024[5].